Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan.

Shin KobayashiShinichiro TakahashiNaoki TakahashiToshiki MasuishiHirokazu ShojiEiji ShinozakiTatsuro YamaguchiMotohiro KojimaNaoto GotohdaShogo NomuraTakayuki YoshinoHiroya Taniguchi

Published in: Annals of surgical oncology (2020)

Since the early onset unresectable recurrence rate was very high, systemic chemotherapy should be considered for resectable BRAF V600E mutant CRLM. A novel perioperative treatment strategy is needed to improve the survival of such patients.

Keyphrases

liver metastases
early onset
wild type
locally advanced
end stage renal disease
late onset
ejection fraction
prognostic factors
newly diagnosed
chronic kidney disease
lymph node
patients undergoing
clinical trial
peritoneal dialysis
radiation therapy
cross sectional
patient reported outcomes
smoking cessation